Literature DB >> 9497245

Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.

B M Manning1, K A Quane, H Ording, A Urwyler, V Tegazzin, M Lehane, J O'Halloran, E Hartung, L M Giblin, P J Lynch, P Vaughan, K Censier, D Bendixen, G Comi, L Heytens, K Monsieurs, T Fagerlund, W Wolz, J J Heffron, C R Muller, T V McCarthy.   

Abstract

Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that is triggered in genetically predisposed individuals by common anesthetics and muscle relaxants. The ryanodine receptor (RYR1) is mutated in a number of MH pedigrees, some members of which also have central core disease (CCD), an inherited myopathy closely associated with MH. Mutation screening of 6 kb of the RYR1 gene has identified four adjacent novel mutations, C6487T, G6488A, G6502A, and C6617T, which result in the amino acid alterations Arg2163Cys, Arg2163His, Val2168Met, and Thr2206Met, respectively. Collectively, these mutations account for 11% of MH cases and identify the gene segment 6400-6700 as a mutation hot spot. Correlation analysis of the in vitro contracture-test data available for pedigrees bearing these and other RYR1 mutations showed an exceptionally good correlation between caffeine threshold and tension values, whereas no correlation was observed between halothane threshold and tension values. This finding has important ramifications for assignment of the MH-susceptible phenotype, in genotyping studies, and indicates that assessment of recombinant individuals on the basis of caffeine response is justified, whereas assessment on the basis of halothane response may be problematic. Interestingly, the data suggest a link between the caffeine threshold and tension values and the MH/CCD phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9497245      PMCID: PMC1376943          DOI: 10.1086/301748

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  35 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia.

Authors:  B M Manning; K A Quane; P J Lynch; A Urwyler; V Tegazzin; R Krivosic-Horber; K Censier; G Comi; P Adnet; W Wolz; J Lunardi; C R Muller; T V McCarthy
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

3.  A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees.

Authors:  R L Robinson; N Monnier; W Wolz; M Jung; A Reis; G Nuernberg; J L Curran; K Monsieurs; P Stieglitz; L Heytens; R Fricker; C van Broeckhoven; T Deufel; P M Hopkins; J Lunardi; C R Mueller
Journal:  Hum Mol Genet       Date:  1997-06       Impact factor: 6.150

4.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia.

Authors:  W Kalow; B A Britt; M E Terreau; C Haist
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

5.  Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred.

Authors:  P J Lynch; R Krivosic-Horber; H Reyford; N Monnier; K Quane; P Adnet; G Haudecoeur; I Krivosic; T McCarthy; J Lunardi
Journal:  Anesthesiology       Date:  1997-03       Impact factor: 7.892

6.  Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle.

Authors:  S O'Driscoll; T V McCarthy; H M Eichinger; W Erhardt; F Lehmann-Horn; A Herrmann-Frank
Journal:  Biochem J       Date:  1996-10-15       Impact factor: 3.857

7.  Central core disease. Clinical features in 13 patients.

Authors:  A Shuaib; R T Paasuke; K W Brownell
Journal:  Medicine (Baltimore)       Date:  1987-09       Impact factor: 1.889

8.  Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum.

Authors:  F Zorzato; J Fujii; K Otsu; M Phillips; N M Green; F A Lai; G Meissner; D H MacLennan
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

9.  A mutation in the human ryanodine receptor gene associated with central core disease.

Authors:  Y Zhang; H S Chen; V K Khanna; S De Leon; M S Phillips; K Schappert; B A Britt; A K Browell; D H MacLennan
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

10.  Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene.

Authors:  T Deufel; R Sudbrak; Y Feist; B Rübsam; I Du Chesne; K L Schäfer; N Roewer; T Grimm; F Lehmann-Horn; E J Hartung
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

View more
  19 in total

1.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.

Authors:  V Barone; O Massa; E Intravaia; A Bracco; A Di Martino; V Tegazzin; S Cozzolino; V Sorrentino
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

2.  Defects in Ca2+ release associated with local expression of pathological ryanodine receptors in mouse muscle fibres.

Authors:  Romain Lefebvre; Claude Legrand; Estela González-Rodríguez; Linda Groom; Robert T Dirksen; Vincent Jacquemond
Journal:  J Physiol       Date:  2011-10-03       Impact factor: 5.182

3.  Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor.

Authors:  G Avila; R T Dirksen
Journal:  J Gen Physiol       Date:  2001-09       Impact factor: 4.086

Review 4.  Neurological channelopathies.

Authors:  T D Graves; M G Hanna
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

5.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

6.  Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1.

Authors:  Robert T Dirksen; Guillermo Avila
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

7.  Voltage-dependent calcium release in human malignant hyperthermia muscle fibers.

Authors:  A Struk; F Lehmann-Horn; W Melzer
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

8.  Effects of Mg(2+) and SR luminal Ca(2+) on caffeine-induced Ca(2+) release in skeletal muscle from humans susceptible to malignant hyperthermia.

Authors:  Adrian M Duke; Philip M Hopkins; Derek S Steele
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

9.  Diagnostic yield and clinical impact of exome sequencing in early-onset scoliosis (EOS).

Authors:  Sen Zhao; Yuanqiang Zhang; Weisheng Chen; Weiyu Li; Shengru Wang; Lianlei Wang; Yanxue Zhao; Mao Lin; Yongyu Ye; Jiachen Lin; Yu Zheng; Jiaqi Liu; Hengqiang Zhao; Zihui Yan; Yongxin Yang; Yingzhao Huang; Guanfeng Lin; Zefu Chen; Zhen Zhang; Sen Liu; Lichao Jin; Zhaoyang Wang; Jingdan Chen; Yuchen Niu; Xiaoxin Li; Yong Wu; Yipeng Wang; Renqian Du; Na Gao; Hong Zhao; Ying Yang; Ying Liu; Ye Tian; Wenli Li; Yu Zhao; Jia Liu; Bin Yu; Na Zhang; Keyi Yu; Xu Yang; Shugang Li; Yuan Xu; Jianhua Hu; Zhe Liu; Jianxiong Shen; Shuyang Zhang; Jianzhong Su; Anas M Khanshour; Yared H Kidane; Brandon Ramo; Jonathan J Rios; Pengfei Liu; V Reid Sutton; Jennifer E Posey; Zhihong Wu; Guixing Qiu; Carol A Wise; Feng Zhang; James R Lupski; Jianguo Zhang; Nan Wu
Journal:  J Med Genet       Date:  2020-05-07       Impact factor: 6.318

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.